The local medical sector is excited with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor showing impressive results in early trials for treating obesity. This therapy suggests a powerful https://webookmarks.com/story7438115/the-new-retatrutide-australia-a-emerging-hope-for-weight-management